Sigma-Aldrich Acquires Pharmorphix to Expand R&D Offering
The mid-year addition of Pharmorphix, which had sales of roughly $5 million over the past 12 months, will not have a material impact on Sigma- Aldrich's sales. The acquisition is expected to help the Company achieve its growth goals over the next several years and is expected to be neutral to mildly accretive to earnings in 2006, with no initial charges. All current employees in good standing, including the existing Pharmorphix management team, will remain with the company. Terms of the purchase, which were not disclosed, were paid in cash.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.